US NIH National Institute of Allergy and Infectious Diseases: Accelerating Malaria Vaccine Discovery (R01 clinical trial not allowed)

This supports early-phase translational research that will generate new vaccine candidates suitable for further downstream development and clinical evaluation. Studies that lead to discovery of new vaccine candidates that prevent infection, ameliorate disease or interrupt transmission caused by human malaria parasites, especially P. falciparum and P. vivax, are encouraged.

This opportunity uses the R01 Research Project Grant funding mechanism.

Funding & Duration

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Date

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding, Sciences and tagged . Bookmark the permalink.

Comments are closed.